In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

By T. T. Smith, S. B. Stephan, H. Moffett, L. McKnight, Weihang Ji, D. Reiman, Emmy Bonagofski, M. Wohlfahrt, S. Pillai, M. Stephan. Nature Nanotechnology, 2017

683 citations recorded by the source corpus.

An emerging approach for treating cancer involves programming patient-derived T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can combat tumour cells once they are reinfused. Although trials of this therapy have produced impressive results, the in vitro methods they require to generate large numbers of tumour-specific T cells are too elaborate for widespread application to treat cancer patients. Here, we describe a method to quickly program circulating T cells with tumour-recognizing capabilities, thus avoiding these complications. Specifically, we demonstrate that DNA-carrying nanoparticles can efficiently introduce leukaemia-targeting CAR genes into T-cell nuclei, thereby bringing about long-term disease remission. These polymer nanoparticles are easy to manufacture in a stable form, which simplifies storage and reduces cost. Our technology may therefore provide a practical, broadly applicable treatment that can generate anti-tumour immunity ‘on demand’ for oncologists in a variety of settings.

Subfields: Biomedical Engineering, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/f33e7d95e4fdb7df4c690d85bbae2ec76e1e463f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. Lulu Cai
  2. Yajun Wang
  3. Rehmat Islam
  4. T. Gong
  5. Yangbao Miao
  6. Rongsheng Tong
  7. Hongmei Liu
  8. Yang Lei

Citations in the corpus